全部文献期刊学位论文会议报纸专利标准年鉴图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Marie-Claude Beauchamp , Paul Abou Nader ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)Impairment of homologous recombination (HR) is found in close to 50 % of ovarian and breast cancer. Tumors with BRCA1 mutations show increased expression of the Insulin-like growth factor type 1 receptor (IGF-1R). We previously have shown that inhibit...
作者:Marie-Claude Beauchamp , Hubert Fleury ...
来源:[J].BMC Medicine(IF 6.679), 2015, Vol.13 (1)Springer
摘要:Abstract(#br) Background(#br)PARP inhibitors have shown promising clinical results in cancer patients carrying BRCA1/2 mutations. Their clinical efficacy could logically be influenced by PARP1 protein levels in patient tumors.(#br) Methods(#br)We screened three cohorts of pa...
作者:Marie-Claude Beauchamp , Libin Yuan
来源:[J].PLoS ONE(IF 3.73), 2017, Vol.12 (8)DOAJ
摘要:The transmembrane emp24 domain/p24 (TMED) family are essential components of the vesicular transport machinery. Members of the TMED family serve as cargo receptors implicated in selection and packaging of endoplasmic reticulum (ER) luminal proteins into coatomer (COP) II coa...
作者:Marie-Claude Beauchamp , Amber Yasmeen ...
来源:[J].Gynecologic Oncology(IF 3.929), 2014, Vol.134 (3), pp.607-614Elsevier
摘要:Abstract(#br)Background(#br)Metformin has been associated with reduced cancer risk. The mechanisms underlying this cancer protective effect remain unknown.(#br)Methods(#br)“Window of opportunity” study of metformin in women with operable endometrial cancer (EC). Eleven newly...
作者:Marie-Claude Beauchamp , Ariane Knafo ...
来源:[J].Gynecologic Oncology(IF 3.929), 2009, Vol.115 (2), pp.193-198Elsevier
摘要:Abstract(#br)Objective(#br)To evaluate the anti-neoplastic activity of BMS-536924, an IGF-1R inhibitor, in epithelial ovarian cancer and its capacity to potentiate the effect of a PARP inhibitor, 3-aminobenzamide.(#br)Methods(#br)OVCAR-3, OVCAR-4, SKOV-3 and TOV-81D cell lines we...
作者:Marie-Claude Beauchamp , Jing Gu ...
来源:[J].Gynecologic Oncology(IF 3.929), 2008, Vol.110 (2), pp.246-250Elsevier
摘要:Abstract(#br)Objective(#br)Metformin, a commonly used drug in the treatment of type II diabetes, may reduce cancer risk and improve cancer prognosis. We evaluated its effect on epithelial ovarian cancer cell lines.(#br)Methods(#br)The OVCAR-3 and OVCAR-4 cell lines were exposed t...
作者:Marie-Claude Beauchamp , Ettie Piura ...
来源:[J].Gynecologic Oncology(IF 3.929), 2011, Vol.121 (3), pp.492-498Elsevier
摘要:Abstract(#br)Objective(#br)The aims of the study were to evaluate the ability of metformin to induce apoptosis in epithelial ovarian cancer cell lines and to identify the pathways involved in this effect.(#br)Methods(#br)After treatment with metformin and/or cisplatin, OVCAR-3 an...
作者:Ling Li , Marie-Claude Beauchamp , Geneviève Renier
来源:[J].Atherosclerosis(IF 3.706), 2002, Vol.165 (1), pp.101-110Elsevier
摘要:Abstract(#br)Peroxisome proliferator-activated receptors (PPARs) are transcriptional factors which mediate pleiotropic effects including regulation of genes involved in lipid metabolism and control of inflammation. In the present study, we measured the in vitro effects of PP...
作者:Marie-Claude Beauchamp , Joshua Rosenblatt ...
来源:[J].Biochemical and Biophysical Research Communications(IF 2.406), 2011, Vol.414 (4), pp.694-699Elsevier
摘要:Abstract(#br)Epidemiologic and laboratory data suggesting that metformin has antineoplastic activity have led to ongoing clinical trials. However, pharmacokinetic issues that may influence metformin activity have not been studied in detail. The organic cation transporter 1 (OCT1)...
作者:Marie-Claude Beauchamp , Amber Yasmeen
来源:[J].International Journal of Gynecological Cancer(IF 1.941), 2016, Vol.26 (7), pp.1213-1221Wolters Kluwer
摘要:PURPOSE: Epithelial-mesenchymal transition (EMT) is a critical process for cancer metastasis and recurrence. Metformin, an effective oral antidiabetic drug, has been associated with decreased cancer risk and mortality. In this pilot study, we started to evaluate the effect of met...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×